AnaptysBio Inc ANAB:NASDAQ

Last Price$21.40NASDAQ Previous Close - Last Trade as of 4:00PM ET 3/24/23

Today's Change-0.23(1.06%)
Bid (Size)$21.39 (4)
Ask (Size)$21.44 (39)
Day Low / High$20.63 - 21.85
Volume176.0 K

View Biotechnology IndustryPeer Comparison as of 03/24/2023


AnaptysBio Inc ( NASDAQ )

Price: $21.40
Change: -0.23 (1.06%)
Volume: 176.0 K
4:00PM ET 3/24/2023

Immunitybio Inc ( NASDAQ )

Price: $1.64
Change: +0.18 (12.33%)
Volume: 4.0 M
4:00PM ET 3/24/2023

ANI Pharmaceuticals Inc ( NASDAQ )

Price: $37.61
Change: -0.21 (0.56%)
Volume: 60.3 K
4:00PM ET 3/24/2023

ADMA Biologics Inc ( NASDAQ )

Price: $3.32
Change: +0.21 (6.75%)
Volume: 3.9 M
4:00PM ET 3/24/2023

Anavex Life Sciences Corp ( NASDAQ )

Price: $8.72
Change: +0.04 (0.46%)
Volume: 1.1 M
4:00PM ET 3/24/2023

Read more news Recent News

Sector Update: Health Care Stocks Steady Friday Afternoon While Other Sectors Rebound
4:08PM ET 1/13/2023 MT Newswires

Health care stocks were moderately higher Friday afternoon, with the NYSE Health Care Index rising 0.6% and the Health Care Select Sector SPDR Fund (XLV)...

Sector Update: Health Care Standing Firm as Broader Markets Catch Up
1:47PM ET 1/13/2023 MT Newswires

Health care stocks were moderately higher Friday afternoon, with the NYSE Health Care Index rising 0.4% and the Health Care Select Sector SPDR Fund (XLV)...

AnaptysBio Approves $50 Million Share Buyback Plan; Stock Gains
9:36AM ET 1/13/2023 MT Newswires

AnaptysBio (ANAB) said Friday its board has approved a share repurchase plan for up to $50 million worth of its common shares. The buyback program is...

Raymond James Downgrades AnaptysBio to Market Perform From Outperform
8:31AM ET 1/06/2023 MT Newswires

AnaptysBio (ANAB) has an average rating of hold and price targets ranging from $23 to $44, according to analysts polled by Capital IQ. (MT Newswires covers...

View all Commentary and Analysis

Lantheus Holdings Rules The Medical Diagnostics Business World
3:28PM ET 7/06/2022 Seeking Alpha

Company Profile

Business DescriptionAnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA. View company web site for more details
Address10770 Wateridge Circle
San Diego, California 92121-5801
Number of Employees78
Recent SEC Filing03/01/2023S-8
President, Chief Executive Officer & DirectorDaniel R. Faga
Chief Operating Officer & General CounselEric J. Loumeau
Chief Financial OfficerDennis M. Mulroy
Chief Medical OfficerPaul F. Lizzul

Company Highlights

Price Open$21.60
Previous Close$21.63
52 Week Range$18.20 - 32.44
Market Capitalization$597.7 M
Shares Outstanding27.9 M
SectorHealth Technology
Next Earnings Announcement05/03/2023

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.58
Beta vs. S&P 500N/A
Revenue$5.0 M
Net Profit Margin-1,251.33%
Return on Equity-43.83%

Analyst Ratings as of 03/02/2023

Consensus RecommendationConsensus Icon
Powered by Factset